Nivolumab

Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study
Kamran A Ahmed, Younchul Kim, Sungjune Kim, Min Hsuan Wang, Michelle DeJesus, John A Arrington, Aixa E Soyano, Avan J Armaghani, Ricardo L B Costa, Loretta S Loftus, Marilin Rosa, Jimmy J Caudell, Roberto Diaz, Arnold B Etame, Nam D Tran, Hatem Soliman, Brian J Czerniecki, Peter A Forsyth, Hsiang-Hsuan Michael Yu, Hyo S Han

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011432; DOI: 10.1136/jitc-2024-011432
Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma
Christophe Maritaz, David Combarel, Cécile Dalban, Louis Blondel, Sophie Broutin, Aurelien Marabelle, Laurence Albiges, Angelo Paci

Journal for ImmunoTherapy of Cancer Jan 2025, 13 (1) e010059; DOI: 10.1136/jitc-2024-010059
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)
Hirokazu Shoji, Chie Kudo-Saito, Kengo Nagashima, Hiroshi Imazeki, Kai Tsugaru, Naoki Takahashi, Takeshi Kawakami, Yusuke Amanuma, Takeru Wakatsuki, Naohiro Okano, Yukiya Narita, Yoshiyuki Yamamoto, Rika Kizawa, Kei Muro, Kazunori Aoki, Narikazu Boku

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (11) e010174; DOI: 10.1136/jitc-2024-010174
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
Nicolas Zhou, Cheuk H Leung, William N William, Annikka Weissferdt, Apar Pataer, Myrna C B Godoy, Brett W Carter, Frank V Fossella, Anne S Tsao, George R Blumenschein, Xiuning Le, Jianjun Zhang, Ferdinandos Skoulidis, Jonathan M Kurie, Mehmet Altan, Charles Lu, Bonnie S Glisson, Lauren A Byers, Yasir Y Elamin, Reza J Mehran, David C Rice, Garrett L Walsh, Wayne L Hofstetter, Jack A Roth, Hai T Tran, Jia Wu, Luisa M Solis Soto, Humam Kadara, Stephen G Swisher, Ara A Vaporciyan, Don L Gibbons, Heather Y Lin, J Jack Lee, John V Heymach, Marcelo V Negrao, Boris Sepesi, Tina Cascone

Journal for ImmunoTherapy of Cancer Oct 2024, 12 (10) e009677; DOI: 10.1136/jitc-2024-009677
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
Idris Bahce, Chris Dickhoff, Famke L Schneiders, Joris Veltman, David J Heineman, Sayed M S Hashemi, Anne Vrijmoet, Ilias Houda, Ezgi B Ulas, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Lilian J Meijboom, Daniela E Oprea-Lager, Febe van Maldegem, Marieke F Fransen, Tanja D de Gruijl, Teodora Radonic, Suresh Senan

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e009799; DOI: 10.1136/jitc-2024-009799
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
Anna K Maloney, Anita Giobbie-Hurder, Nikita Katukota, Miklos C Fogarasi, Patrick A Ott, F Stephen Hodi, Tamara A Sussman, Ann W Silk, Rizwan Haq, David Liu, Megan Insco, Elizabeth I Buchbinder

Journal for ImmunoTherapy of Cancer Aug 2024, 12 (8) e009061; DOI: 10.1136/jitc-2024-009061
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
Xizi Hu, Shoiab M Bukhari, Carly Tymm, Kieran Adam, Shalom Lerrer, Brian S Henick, Robert J Winchester, Adam Mor

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008482; DOI: 10.1136/jitc-2023-008482
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino, Mark Kochenderfer, Elena Elez, Spencer H Shao, Dustin Deming, Regan Holdridge, Timothy Larson, Eric Chen, Amit Mahipal, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell, Jin Yao, Josep Tabernero

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008409; DOI: 10.1136/jitc-2023-008409
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason J Luke, Ignacio Melero, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e007364; DOI: 10.1136/jitc-2023-007364
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
Shogo Takei, Yosuke Tanaka, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima, Hideaki Bando, Saori Mishima, Toshihide Ueno, Shinya Kojima, Masashi Wakabayashi, Naoya Sakamoto, Motohiro Kojima, Takeshi Kuwata, Takayuki Yoshino, Hiroyoshi Nishikawa, Hiroyuki Mano, Itaru Endo, Kohei Shitara, Akihito Kawazoe

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e008210; DOI: 10.1136/jitc-2023-008210

Main menu

Nivolumab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Nivolumab

Pages